CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 19-487/S-023

Name: Imodium A-D (Loperamide HCl) Liquid

Sponsor: McNeil Consumer & Specialty Pharmaceuticals

Approval Date: June 8, 2005
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-487/S-023

CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Approvable Letter</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>Labeling Review</td>
</tr>
<tr>
<td>Medical Review</td>
</tr>
<tr>
<td>Chemistry Review</td>
</tr>
<tr>
<td>Pharmacology / Toxicology Review</td>
</tr>
<tr>
<td>Statistical Review</td>
</tr>
<tr>
<td>Microbiology Review</td>
</tr>
<tr>
<td>Clinical Pharmacology / Biopharmaceutics Review</td>
</tr>
<tr>
<td>Administrative and Correspondence Documents</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 19-487/S-023

APPROVAL LETTER
NDA 19-487/S-023

McNeil Consumer & Specialty Products
Attention: Carolyn Zlogar
Manager, CMC Regulatory
7050 Camp Hill Road
Fort Washington, PA 19034

Dear Ms. Zlogar:


This supplemental new drug application proposes a new 12 oz bottle package size and the addition of a (b) (4) production batch.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (immediate container label submitted on December 22, 2004), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 19-487/S-023." Approval of this submission by FDA is not required before the labeling is used.

We also recommend the following labeling changes. These changes are not a condition of approval. You may incorporate these changes in the labeling at the next time of printing and submit the revised labeling in the following annual report.

1) Vertically align the bulleted statements in the, “Stop use and ask a doctor if” and “Directions” sections according to 21 CFR 201.66(d)(4), so that the bulleted statements appearing on each subsequent horizontal line of text under a heading or subheading are vertically aligned with the bulleted statements appearing on the previous line.

2) Move the statement “Keep out of reach of children” to a new line, in alignment with the other left justified Drug Facts headings to conform with 21 CFR 201.66(b)(7) and (d)(1).
If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call LCDR Keith Olin, Regulatory Project Manager, at (301) 827-2293.

Sincerely,

[See appended electronic signature page]

Curtis Rosebraugh, M.D., M.P.H.
Acting Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Curtis Rosebraugh
6/8/05 07:51:04 AM
APPLICATION NUMBER:
NDA 19-487/S-023

LABELING
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-487/S-023

LABELING REVIEW
Division of OTC Drug Products Labeling Review for an NDA Supplement

NDA 19-487 / SCP-023

Submission Date: December 22, 2004
Received Date: December 23, 2004
Drug product: IMODIUM A-D Liquid
Active ingredient: Loperamide HCl
Pharmacological category: anti-diarrheal
Sponsor/Contact: Carolyn Zlogar
Manager, CMC Regulatory Affairs
McNeil Consumer & Specialty Pharmaceuticals
7050 Camp Hill Road
Fort Washington, PA 19034
(215)273-8476

Labeling submitted: 12 oz bottle label
Reviewer: Reynold Tan
Review date: June 1, 2005
Project manager: Keith Olin

Background: In this CBE-30 supplement, the sponsor requested approval of a new bottle size for Imodium A-D Liquid. The sponsor provided a representative label for the proposed 12 oz bottle package, noting that the proposed label is consistent with the labels for the 4 and 8 oz bottles approved on 7/8/04 (NDA 19-487/ S-022).

Concerning that supplement (S-022), FDA requested that the sponsor reposition the tradename “Imodium A-D” such that the “A-D” does not appear to be part of the statement of identity “Loperamide HCl/ Anti-Diarrheal.” Also, FDA requested that the hairline dividing the “Directions” section from the preceding “Keep out of reach of children” warning be replaced with a barline. In this supplement, the sponsor states that these two changes will be reflected in a subsequent annual report.

Reviewer’s Comments:
1) A barline correctly separates the “Directions” section from the preceding “Keep out of reach of children” warning in the “Warnings” section.
Comment: This change had been recommended and is acceptable.

2) The bullets in the “Stop use and ask a doctor if” and “Directions” sections do not conform to format requirements in 21 CFR 201.66(d)(4).
Comment: According to 21 CFR 201.66(d)(4), “additional bulleted statements appearing on each subsequent horizontal line of text under a heading or subheading shall be vertically aligned
with the bulleted statements appearing on the previous line.” The bullets in the “Stop use and ask a doctor if” and “Directions” sections should be aligned according to this regulation.

3) The text of the “If pregnant or breast-feeding” and “Keep out of reach of children” warnings wraps over two successive lines.
Comment: The statements “If pregnant or breast-feeding” and “Keep out of reach of children” are defined as headings, according to 21 CFR 201.66(b)(7). All headings must be left justified, according to 21 CFR 201.66(d)(1). Therefore, the statement “Keep out of reach of children” should appear on a new line.

Reviewer’s recommendation: The following comment can be conveyed to the sponsor:

1) Align the bullets in the “Stop use and ask a doctor if” and “Directions” sections according to 21 CFR 201.66(d)(4), which states that additional bulleted statements appearing on each subsequent horizontal line of text under a heading or subheading shall be vertically aligned with the bulleted statements appearing on the previous line.

2) To conform with 21 CFR 201.66(b)(7) and (d)(1), move the statement “Keep out of reach of children” to a new line, in alignment with the other left justified Drug Facts headings.

The sponsor should make these changes in the labeling at the next printing and submit the revised labeling in the next annual report.

Reynold Tan, Ph.D.  
IDS/Biologist, HFD-560  

Helen Cothran, B.S.  
Team Leader, HFD-560
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Reynold Tan
6/2/05 11:11:32 AM
INTERDISCIPLINARY

Helen Cothran
6/2/05 01:47:16 PM
INTERDISCIPLINARY
APPLICATION NUMBER:
NDA 19-487/S-023

CHEMISTRY REVIEW
<table>
<thead>
<tr>
<th>Chemistry Review # 1</th>
<th>1. Division</th>
<th>2. NDA Number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HFD-560</td>
<td>19-487</td>
</tr>
</tbody>
</table>

3. **Name and Address of Applicant**  
McNeil Consumer & Specialty Pharmaceuticals  
Attention: Carolyn Zlogar, Manager, CMC Regulatory Affairs  
7050 Camp Hill Road  
Fort Washington, PA 19034  
Phone: 215-273-8476  

4. **Supplement**  
Number: SCP-023  
Letter Date: 12/22/04  
Stamp Date: 12/23/04  
Due Date: 6/23/05  

5. **Name of Drug**  
IMODIUM A-D Liquid  

6. **Nonproprietary Name**  
Loperamide HCl  

7. **Supplement Provides for:**  
A new container size (12 oz) of polypropylene bottles and addition of _production batch_ size for the drug product.  

8. **Amendment(s)**  
N/A  

9. **Pharmacological Category**  
Controls the symptoms of diarrhea, including Traveler's Diarrhea  

10. **How Dispensed**  
OTC  

11. **Related Documents**  
N/A  

12. **Dosage Form**  
Oral Liquid  

13. **Potency(ies)**  
1 mg/7.5mL  

14. **Chemical Name and Structure**  
see USAN  
4-(p-Chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide monohydrochloride, C_{29}H_{31}ClN_{2}O_{2} HCl, Mol. wt. 513.50  

15. **Comment**  
Changes Being Effected in 30 days  
This supplement provides for a new container size (12 oz) of polypropylene (PP) bottles and addition of _production batch_ size for the drug product. The PP resin _used in the proposed bottle size was stated to be the same resin that is currently used in the bottles for the applicant's Infants' Motrin® Drops (NDA 20-603). The closure materials were stated to be the same as those used for the currently approved container size (NDA 19-487/S-022). The Manufacturing process, equipment, and parameters were stated to be similar to those used for the current _batch size. The updated batch formula for the proposed batch size was provided along with the master and executed batch records.  

The supplement included test results of Physicochemical Tests-Plastics <USP 661> and Containers-Permeation Test <USP 671>. The submitted data conforms to the USP requirements. The supplement included three months of stability data at long-term (25°C/60%RH), accelerated (40°C), and cycle (-20°C to +25°C) conditions on one production scale batch in support of the proposed change. The submitted stability data did not indicate any adverse effect on the drug product because of the proposed change.  

16. **Conclusions and Recommendations**  
This supplement is recommended for approval.  
This supplement contains labeling. Action letter will be issued by HFD-560.  

17. **Name**  
Rao Puttagunta, Ph.D., Reviewer  
**Signature**  
**Date**  
5/23/05  

18. **Concurrence**  
John Smith, Ph.D., Chemistry Team Leader
Review Notes

Stability Data Summary

<table>
<thead>
<tr>
<th>No. of Batches /Size</th>
<th>Storage Conditions</th>
<th>Available Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/Production</td>
<td>25°C/60%RH 40°C Cycle (-20°C to +25°C)</td>
<td>3 months 3 months Three cycles at -20°C for 4 days, then at +25°C/60%RH for 3 days</td>
</tr>
</tbody>
</table>

**Evaluation:** Submitted stability data on one production batch of drug product packaged in the proposed 12 oz size bottles conforms to established acceptance criteria, and the data on assay did not show any trends except for random variation and the degradant was not detectable. The submitted data did not indicate any adverse effect on the drug product because of the proposed change. *Adequate.*

**Stability Commitment:** The applicant commits to place the first commercial production batch and annual batches thereafter, packaged in 12 oz PP bottles made with the proposed resin, on long-term stability according to the approved stability protocol. *Adequate.*

**Expiration Period:** The applicant proposed to retain the current expiration dating period of 24 months. *Acceptable.*
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Rao Puttagunta
5/24/05 01:01:30 PM
CHEMIST

John Smith
5/24/05 01:35:01 PM
CHEMIST
APPLICATION NUMBER:
NDA 19-487/S-023

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
NDA 19-487/S-023  

McNeil Consumer & Specialty Products  
Attention: Carolyn Zlogar  
Manager, CMC Regulatory  
7050 Camp Hill Road  
Fort Washington, PA 19034

Dear Ms. Zlogar:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Imodium® A-D (loperamide HCl) Liquid

NDA Number: 19-487

Supplement number: 023

Date of supplement: December 22, 2004

Date of receipt: December 23, 2004

This supplemental application, submitted as a “Supplement - Changes Being Effectuated in 30 days,” proposes a new 12 oz bottle package size and the addition of a production batch.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on February 21, 2005, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be June 23, 2005.
All communications concerning this supplement should be addressed as follows:

**U.S. Postal Service:**
Center for Drug Evaluation and Research
Division of Over the Counter Drug Products, HFD-560
5600 Fishers Lane
Rockville, Maryland 20857

**Courier/Overnight Mail:**
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Over the Counter Drug Products, HFD-560
Attention: Document Room
9201 Corporate Blvd.
Rockville, Maryland 20850

If you have any questions, call Laura Shay, Regulatory Project Manager, at (301) 827-2274.

Sincerely yours,

[See appended electronic signature page]

Leah Christl, Ph.D.
Acting Chief, Project Management Staff
Division of Over the Counter Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Leah Christl
2/2/05 09:51:06 AM